表紙
市場調查報告書

女性用避孕器:開發中產品分析

Female Contraception - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 363113
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
女性用避孕器:開發中產品分析 Female Contraception - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 102 Pages
簡介

本報告提供女性用避孕器的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

女性用避孕器概要

女性用避孕器的開發

  • 開發中產品的概要
  • 開發中產品比較分析

女性用避孕器:企業開發中的治療藥

女性用避孕器:大學/機關研究中的治療藥

女性用避孕器:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

女性用避孕器:企業開發中的產品

女性用避孕器:大學/機關研究中的產品

女性用避孕器治療藥的開發企業

  • Agile Therapeutics, Inc.
  • ANI Pharmaceuticals, Inc.
  • Evofem, Inc.
  • Mithra Pharmaceuticals S.A.
  • Orbis Biosciences, Inc.

女性用避孕器:評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

簡介

女性用避孕器:暫停中的計劃

女性用避孕器:中止開發的產品

女性用避孕器:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11746IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H2 2019, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 5, 3, 12 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Female Contraception - Overview
  • Female Contraception - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Female Contraception - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Female Contraception - Companies Involved in Therapeutics Development
    • Agile Therapeutics Inc
    • Evestra Inc
    • Evofem Biosciences Inc
  • Exeltis Pharmaceuticals Holding SL
    • Hervana Ltd
    • Hydra Biosciences Inc
    • Luye Pharma Group Ltd
    • MedinCell SA
    • Micron Biomedical Inc
    • Mithra Pharmaceuticals SA
    • Mucommune LLC
    • Orbis Biosciences Inc
    • Orion Biotechnology Canada Ltd
    • Ovastasis LLC
    • Teva Pharmaceutical Industries Ltd
    • Viramal Ltd
    • Yaso Therapeutics Inc
    • YourChoice Therapeutics Inc
  • Female Contraception - Drug Profiles
    • (dienogest + ethinylestradiol) PR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (drospirenone + estetrol) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (estradiol + segesterone acetate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (ethinyl estradiol + levonorgestrel) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (ethinylestradiol + gestodene) ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-200 ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-200 SP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-890 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Amphora - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DARE-RH1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-317 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-508 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-625 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etonogestrel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etonogestrel ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HER-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levonorgestrel SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDC-WWM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MM-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OB-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PPCM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-003296 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 to Agonize Progesterone Receptor for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Progesterone Receptor for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Female and Male Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TV-46046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Female Contraception - Dormant Projects
  • Female Contraception - Discontinued Products
  • Female Contraception - Product Development Milestones
    • Featured News & Press Releases
      • Dec 03, 2019: PDL BioPharma congratulates Evofem Biosciences on achieving major regulatory and clinical milestones with its lead product candidate Amphora
      • Nov 28, 2019: Medincell receives $19 million grant for Its mdc-WWM program
      • Nov 26, 2019: Evofem Biosciences resubmits New Drug Application to U.S. FDA for Amphora for the prevention of Pregnancy
      • Nov 14, 2019: Agile Therapeutics announces FDA extension of Twirla NDA review period
      • Oct 30, 2019: Agile Therapeutics announces favorable outcome of FDA advisory committee meeting for its investigational transdermal contraceptive patch, Twirla (AG200-15)
      • Oct 16, 2019: Presentation of Estelle phase III results at the 13th Meeting of the European Society of Gynecology
      • Aug 08, 2019: Mithra obtains crucial additional Estelle patent in Japan
      • Aug 05, 2019: Evofem Biosciences reports additional data from phase 3 ampower study of amphora for hormone-free birth control
      • Jul 23, 2019: Jubilant Cadista Pharmaceuticals issues voluntary nationwide recall of Drospirenone and Ethinyl Estradiol Tablets, USP, due to out-of-specification dissolution test results
      • Jul 18, 2019: Agile Therapeutics appoints chief financial officer
      • Jun 28, 2019: Agile Therapeutics presents on AG20015 at Women's Health 2019
      • Jun 24, 2019: Agile Therapeutics announces FDA Advisory Committee Meeting for its investigational transdermal low-dose contraceptive patch, Twirla (AG200-15)
      • May 22, 2019: Agile Therapeutics announces FDA acceptance of the NDA resubmission of Twirla
      • May 17, 2019: Agile Therapeutics resubmits New Drug Application (NDA) for its present new dtransdermal low-dose contraceptive patch, Twirla
      • May 03, 2019: Agile Therapeutics to present combined safety data from three phase 3 studies at the 2019 ACOG Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Female Contraception, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Female Contraception - Pipeline by Agile Therapeutics Inc, H2 2019
  • Female Contraception - Pipeline by Evestra Inc, H2 2019
  • Female Contraception - Pipeline by Evofem Biosciences Inc, H2 2019
  • Female Contraception - Pipeline by Exeltis Pharmaceuticals Holding SL, H2 2019
  • Female Contraception - Pipeline by Hervana Ltd, H2 2019
  • Female Contraception - Pipeline by Hydra Biosciences Inc, H2 2019
  • Female Contraception - Pipeline by Luye Pharma Group Ltd, H2 2019
  • Female Contraception - Pipeline by MedinCell SA, H2 2019
  • Female Contraception - Pipeline by Micron Biomedical Inc, H2 2019
  • Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H2 2019
  • Female Contraception - Pipeline by Mucommune LLC, H2 2019
  • Female Contraception - Pipeline by Orbis Biosciences Inc, H2 2019
  • Female Contraception - Pipeline by Orion Biotechnology Canada Ltd, H2 2019
  • Female Contraception - Pipeline by Ovastasis LLC, H2 2019
  • Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
  • Female Contraception - Pipeline by Viramal Ltd, H2 2019
  • Female Contraception - Pipeline by Yaso Therapeutics Inc, H2 2019
  • Female Contraception - Pipeline by YourChoice Therapeutics Inc, H2 2019
  • Female Contraception - Dormant Projects, H2 2019
  • Female Contraception - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Female Contraception - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Female Contraception, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top